A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Saved in:
| Title: | A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. |
|---|---|
| Authors: | Hanna GJ; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA. Electronic address: glenn_hanna@dfci.harvard.edu., ONeill A; Department of Data Science, Dana-Farber Cancer Institute, Boston, USA., Cutler JM; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Flynn M; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Vijaykumar T; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Clark JR; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Wirth LJ; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Lorch JH; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA., Park JC; Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, USA., Mito JK; Department of Pathology, Brigham & Women's Hospital, Boston, USA., Lohr JG; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, USA., Kaufman J; Adenoid Cystic Carcinoma Research Foundation, USA., Burr NS; Adenoid Cystic Carcinoma Research Foundation, USA., Zon LI; Department of Stem Cell and Regenerative Biology, Boston Children's Hospital and Harvard Medical School, Boston, USA., Haddad RI; Department of Medical Oncology, Center for Head & Neck Oncology, Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, Boston, USA. |
| Source: | Oral oncology [Oral Oncol] 2021 Aug; Vol. 119, pp. 105366. Date of Electronic Publication: 2021 Jun 03. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
